Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that it will redeem the remaining approximately $500 million aggregate principal amount of its outstanding 6.75% Senior Notes due …
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) tick higher in pre-market trading Monday, after the healthcare firm announced that it has used the …
The closing of the $820 million divestiture of Dendreon to Sanpower Group boosts Valeant Pharmaceuticals Intl Inc (NYSE:VRX) liquidity position, but it does nothing …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA accepted the New Drug Application (NDA) for NER1006 (PLENVU®*) a novel, …
Valeant’s Execution Has Continued to Meet Cantor’s Expectations
On June 20, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) presented at the Goldman Sachs Second Annual Leveraged Finance Conference. During the Q&A session, CFO Paul Herendeen stated, …
Balyasny Asset Management’s Dmitry Balyasny has adjusted some crucial stocks in the fund’s portfolio in Q1. Here we examine his latest moves on …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced that Bausch + Lomb …
Valeant: Challenges Pose Significant Downside Risk Mizuho analyst Irina Rivkind Koffler remains bearish on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock despite recent rally. Koffler reiterates an Underperform …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced Arthur J. Shannon has joined the company as senior vice president, head of Investor Relations and Communications.
